In-Silico Characterization of Estrogen Reactivating β-Glucuronidase Enzyme in GIT Associated Microbiota of Normal Human and Breast Cancer Patients.


Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
27 08 2022
Historique:
received: 09 08 2022
revised: 22 08 2022
accepted: 24 08 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Estrogen circulating in blood has been proved to be a strong biomarker for breast cancer. A β-glucuronidase enzyme (GUS) from human gastrointestinal tract (GIT) microbiota including probiotics has significant involvement in enhancing the estrogen concentration in blood through deconjugation of glucuronidated estrogens. The present project has been designed to explore GIT microbiome-encoded GUS enzymes (GUSOME) repertoire in normal human and breast cancer patients. For this purpose, a total of nineteen GUS enzymes from human GIT microbes, i.e., seven from healthy and twelve from breast cancer patients have been focused on. Protein sequences of enzymes retrieved from UniProt database were subjected to ProtParam, CELLO2GO, SOPMA (secondary structure prediction method), PDBsum (Protein Database summaries), PHYRE2 (Protein Homology/AnalogY Recognition Engine), SAVES v6.0 (Structure Validation Server), MEME version 5.4.1 (Multiple Em for Motif Elicitation), Caver Web server v 1.1, Interproscan and Predicted Antigenic Peptides tool. Analysis revealed the number of amino acids, isoelectric point, extinction coefficient, instability index and aliphatic index of GUS enzymes in the range of 586−795, 4.91−8.92, 89,980−155,075, 25.88−40.93 and 71.01−88.10, respectively. Sub-cellular localization of enzyme was restricted to cytoplasm and inner-membrane in case of breast cancer patients’ bacteria as compared to periplasmic space, outer membrane and extracellular space in normal GIT bacteria. The 2-D structure analysis showed α helix, extended strand, β turn and random coil in the range of 27.42−22.66%, 22.04−25.91%, 5.39−8.30% and 41.75−47.70%, respectively. The druggability score was found to be 0.05−0.45 and 0.06−0.80 in normal and breast cancer patients GIT, respectively. The radius, length and curvature of catalytic sites were observed to be 1.1−2.8 Å, 1.4−15.9 Å and 0.65−1.4, respectively. Ten conserved protein motifs with p < 0.05 and width 25−50 were found. Antigenic propensity-associated sequences were 20−29. Present study findings hint about the use of the bacterial GUS enzymes against breast cancer tumors after modifications via site-directed mutagenesis of catalytic sites involved in the activation of estrogens and through destabilization of these enzymes.

Identifiants

pubmed: 36140713
pii: genes13091545
doi: 10.3390/genes13091545
pmc: PMC9498756
pii:
doi:

Substances chimiques

Amino Acids 0
Biomarkers 0
Estrogens 0
Glucuronidase EC 3.2.1.31

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Biomed Pharmacother. 2020 Jul;127:110203
pubmed: 32559847
Sci Rep. 2016 Aug 03;6:30751
pubmed: 27485780
J Steroid Biochem. 1980 Feb;13(2):231-44
pubmed: 6991820
Int J Biol Sci. 2017 Nov 1;13(11):1387-1397
pubmed: 29209143
Microbiology (Reading). 2005 Jul;151(Pt 7):2323-2330
pubmed: 16000722
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Breast Cancer Res. 2003;5(5):239-47
pubmed: 12927032
BMC Struct Biol. 2007 Aug 29;7:56
pubmed: 17727703
Biol Pharm Bull. 1995 Sep;18(9):1184-8
pubmed: 8845801
Indian J Med Res. 2011 Jul;134:22-5
pubmed: 21808130
BMC Cancer. 2022 Jan 3;22(1):30
pubmed: 34980006
Structure. 2017 Jul 5;25(7):967-977.e5
pubmed: 28578872
Eur J Med Chem. 2020 Feb 1;187:111921
pubmed: 31835168
J Natl Cancer Inst. 2016 Apr 22;108(8):
pubmed: 27107051
PLoS One. 2014 Jan 08;9(1):e83744
pubmed: 24421902
Breast Cancer Res Treat. 2020 Jan;179(2):287-300
pubmed: 31646389
J Appl Bacteriol. 1989 May;66(5):365-78
pubmed: 2666378
Biol Pharm Bull. 1994 Mar;17(3):423-6
pubmed: 8019510
Appl Biochem Biotechnol. 2012 Jan;166(1):243-57
pubmed: 22072140
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):503-513
pubmed: 32936397
Protein Pept Lett. 2019;26(5):339-347
pubmed: 30816075
Mol Cancer. 2018 Apr 23;17(1):83
pubmed: 29685157
Clin Pharmacokinet. 1997 Jul;33(1):18-31
pubmed: 9250421
FEMS Microbiol Lett. 2012 Sep;334(1):1-15
pubmed: 22568660
J Biol Chem. 2018 Nov 30;293(48):18559-18573
pubmed: 30301767
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Mol Biol Evol. 1987 Jul;4(4):406-25
pubmed: 3447015
Appl Environ Microbiol. 2016 Jul 29;82(16):5039-48
pubmed: 27342554
BMC Microbiol. 2020 Apr 9;20(1):82
pubmed: 32272885
Appl Environ Microbiol. 2006 Sep;72(9):6371-6
pubmed: 16957265
Front Chem. 2020 May 29;8:443
pubmed: 32548091
Science. 2010 Nov 5;330(6005):831-5
pubmed: 21051639
J Transl Med. 2012 Dec 21;10:253
pubmed: 23259758
J Biol Chem. 2019 Dec 6;294(49):18586-18599
pubmed: 31636122
Sci Rep. 2018 Nov 15;8(1):16893
pubmed: 30442969
Oncogene. 2019 Mar;38(12):2092-2107
pubmed: 30442981
Methods Mol Biol. 2021;2231:3-16
pubmed: 33289883
Nucleic Acids Res. 2019 Jul 2;47(W1):W414-W422
pubmed: 31114897
Comput Appl Biosci. 1995 Dec;11(6):681-4
pubmed: 8808585
Biomed Pharmacother. 2018 Oct;106:14-34
pubmed: 29945114
J Steroid Biochem Mol Biol. 2019 Nov;194:105439
pubmed: 31362062
J Clin Gastroenterol. 2011 Sep;45(8):679-83
pubmed: 21301358
Proteins. 2015 Apr;83(4):599-611
pubmed: 25663659
Front Bioeng Biotechnol. 2015 Jun 09;3:82
pubmed: 26106597
Am J Pathol. 2021 Jun;191(6):968-982
pubmed: 33713687
Nucleic Acids Res. 2015 Jan;43(Database issue):D204-12
pubmed: 25348405
J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S58-63
pubmed: 18542041
Science. 2011 Jul 1;333(6038):101-4
pubmed: 21596954
Endocr Relat Cancer. 2016 Feb;23(2):125-34
pubmed: 26647383
Biochem Pharmacol. 2021 Aug;190:114566
pubmed: 33865833
Oncotarget. 2017 Aug 14;8(50):88122-88138
pubmed: 29152146
PLoS One. 2014 Feb 10;9(2):e88328
pubmed: 24520369
Cancer Res. 2007 Mar 1;67(5):2062-71
pubmed: 17332335

Auteurs

Fatima Muccee (F)

School of Biochemistry and Biotechnology, University of Punjab, Lahore 52254, Pakistan.

Shakira Ghazanfar (S)

National Institute for Genomics Advanced Biotechnology (NIGAB), National Agricultural Research Centre (NARC), Islamabad 45500, Pakistan.

Wajya Ajmal (W)

National Institute for Genomics Advanced Biotechnology (NIGAB), National Agricultural Research Centre (NARC), Islamabad 45500, Pakistan.

Majid Al-Zahrani (M)

Biological Science Department, College of Science and Art, King Abdulaziz University, Rabigh 25724, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH